NCT05025410View on ClinicalTrials.gov

Remimazolam and Remifentanil Without Neuromuscular Blocking Agent

CompletedOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
Myoma;UterusPolyp EndometriumUnspecified Condition Associated With Female Genital Organs and Menstrual Cycle
Interventions
DRUG

Remimazolam

Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring

Trial Locations (1)

Unknown

Seoul National University Bundang Hospital, Seongnam

All Listed Sponsors
lead

Seoul National University Bundang Hospital

OTHER

NCT05025410 - Remimazolam and Remifentanil Without Neuromuscular Blocking Agent | Biotech Hunter | Biotech Hunter